The Alloplex approach of activating and expanding immune cells by using a highly engineered training cell line represents a novel cellular therapeutic development platform approach with extraordinary promise fueled by our early emerging clinical safety and efficacy data. While the first generation SUPLEXA cells used an unbiased approach resulting in a final product comprised of multiple cell types, we have already demonstrated that the ENLIST immune training platform can be used to specifically enhance B cells, γδ T cells, and Treg cells. In the future, cells enriched for these specific cell types using this approach may have additional specific applications in infectious diseases and autoimmune indications. The pristine safety profile exhibited so far will undoubtedly facilitate the development of SUPLEXA cells either as a stand-alone therapeutic option or in combination with various biologic cancer therapeutic agents such as tumor targeting antibodies, checkpoint inhibitors and cell engagers. While initial SUPLEXA development has focused on an autologous approach, the integration of allogeneic approaches may also be possible in settings where shorter term bridging therapies are required until the patient’s own cells can be prepared [32,33]. The enhanced second-generation manufacturing methods will also greatly facilitate future developments by increasing process efficiencies and exploiting economies of scale, critical features for making such therapies more accessible to patients.